Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy

<div>Sensitivity and specificity of anti-E2 IgG sialylation (SNA reactivity) changes in discriminating fibrosis stages F0 and F4 as evaluated by receiver operator characteristic (ROC) curve analysis. (a) SNA binding, stage F0 versus F4. (b) SNA/IgG ratio, stage F1-3 versus F4.</div>

Disease Markers

fig4

Figure 4

Figure 4: Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy 

Figure 4 | Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy 